Paragon 28, INC.

Reporting payments is a legal requirement; large totals often reflect large product portfolios.

$43Mgeneral payments (2019-2025)
$49Kresearch payments (2019-2025)
6,519clinicians paid

General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.

General payments by year

2019 $6.1M
2020 $20M
2021 $3.9M
2022 $3.8M
2023 $4.3M
2024 $2.7M
2025 $1.5M

General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.

Products most associated with its payments

Specialties it works with most

Orthopaedic Surgery $18M
Foot and Ankle Surgery $10M
Foot & Ankle Surgery $9.3M
Podiatrist $3.4M
Foot Surgery $599K
Sports Medicine (Podiatrist) $576K

Clinicians with the largest reported totals

Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.

ClinicianLocationSpecialtyGeneral payments (2019-2025)
Mark Myerson Baltimore, MD Orthopaedic Surgery $9,773,541.13
David Thordarson Los Angeles, CA Orthopaedic Surgery $2,265,091.64
Michael Houghton Fort Collins, CO Foot and Ankle Surgery $2,013,663.99
Thomas Sangiovanni Coral Gables, FL Foot and Ankle Surgery $2,005,900.14
Mark Dalton Austin, TX Foot and Ankle Surgery $1,871,414.34
Johannes Coetzee Edina, MN Foot and Ankle Surgery $1,651,413.12
David Welker Miamisburg, OH Orthopaedic Surgery $1,650,000.00
Shayne Jensen Panama City, FL Foot & Ankle Surgery $1,238,207.48
Thomas Chang Santa Rosa, CA Foot & Ankle Surgery $1,171,723.98
Jeffrey Christensen Everett, WA Foot & Ankle Surgery $826,157.48

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.